TEH SENG Pharmaceutical Mfg. Co., Ltd.

NT$71.20As of Sun 8 Nov 2026, 12:00 UTC

TPEx:7860Healthcare

Country Taiwan

PE (Fwd) 42.17

TSR 10Y CAGR —

Div yield —

ROE 9.42%

Drug Manufacturers (Specialty & Generic)

Beta (5Y) —

PE TTM 22.19

TSR TTM (8.83%)

Mkt cap NT$2.278B

ROIC 16.41%

SE Grade™

Value

Quality

Moat

1Y Price

Reference

NT$73

2.86%

23.72%

Price below Reference Value

TTM

FYE 31 Dec TWD

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

845.2

RevenueNT$M

—

816.8

902.6

845.2

817.9

1.72%

—

(6.36)

Revenue growth%

—

10.50

(6.36)

(3.23)

2.07

—

27.47

Gross margin%

—

27.47

32.23

27.47

25.10

27.47

—

16.65

Operating margin%

—

15.24

20.96

16.65

14.49

16.65

—

12.19

Net margin%

—

13.53

19.46

12.19

8.56

13.53

—

22.19

P/E ratio (avg)x

—

23.79

32.67

23.79

—

14.26

EV/EBITx

—

15.49

16.58

15.49

—

4.01

FCF yield (avg)%

—

3.74

2.18

3.74

—

10.84

FCF margin%

—

24.18

20.33

10.84

6.10

20.33

—

0.889

FCF / Net incomex

—

1.787

1.045

0.889

0.713

1.045

—

16.41

ROIC%

—

15.09

22.30

16.41

13.90

16.41

—

9.42

Return on equity%

—

11.52

17.29

9.42

6.09

11.52

—

7.34

Return on assets%

—

7.87

11.91

7.34

4.75

7.87

—

3.21

EPSNT$

—

3.45

5.49

3.21

2.18

(3.56%)

—

(41.54)

EPS growth%

—

59.09

(41.54)

(32.08)

8.77

—

34.71

Bookvalue per shNT$

—

29.94

33.54

34.71

36.89

7.67%

—

2.85

FCF per shareNT$

—

6.17

5.73

2.85

1.55

(31.98%)

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

32.00

Shares (diluted)M

—

32.03

32.01

32.12

◌32.12

0.15%

—

(0.35)

Buyback yield%

—

0.06

(0.35)

◌—

(0.15)

—

0.121

D/E ratiox

—

0.237

0.168

0.121

0.114

0.168

—

2.006

Enterprise valueNT$B

—

2.179

1.965

—

LT debtNT$M

—

Peers (US$67.65M)

Cap (US$)

Protect Animal Health…

67.40M

—

Libo Pharma Corp.

57.72M

—

Timing Pharmaceutial…

51.10M

—

Y.S.P. Southeast Asia…

68.19M

10.24x

Capital

TTM

10Y

Leveragex

(1.514)

(0.884)

EBIT/Intx

66.19

Own earn%

—

Sh yield%

(0.35)

(0.15)

Owners

Insiders/Inst%

38.58

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

3/3

Revenue growth years

—

EPS growth years

—

Dividend streakyrs

Op margin range%

15–21

$1 testx

—

Incr. ROIC%

TEH SENG Pharmaceutical Mfg. Co., Ltd. develops, manufactures, and sells pain relieving and cosmetic patches, and biotechnology products. It offers hydrogen patches, oil-based patches, hot-melt patches, transdermal patches, and oral film and sublingual films. The company also provides biocellulose facial masks, bio-rejuvenating facial treatment, skincare products, and daily supplements.

Growth vs revenue

Latest

Trend

2Y CAGR

Rel growth

Revenue

NT$845.2M

1.72%

1.00×

Cost of revenue

NT$613.0M

1.72%

1.00×

Operating expenses

NT$91.49M

(4.30%)

0.89×

Asset mix

Trend

Other

70.99%

Cash and investments

29.01%

Reinvestment returns

3Y median

Trend

Reinvestment rate

(15.23%)

Return on capital

16.41%

Spread over hurdle

13.61%